Defective N-oxidation of sparteine in man: a new phamtacogenetic defect.
Chromosomal assignment of human cytochrome P450 (debrisoquine/ sparteine type) to chromosome 22.
Pharmaco-genetic covariation of defective N-oxidation of
sparteine and 4-hydroxylation of debrisoquine.
Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of
sparteine metabolism.
Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects.
Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients.
An additional allelic variant of the CYP2D6 gene causing impaired metabolism of
sparteine. Hum Genet 1996;97:668-70.
Pharmacokinetics and metabolism of quinidine in extensive and poor metabolizers of sparteine. Eur J Clin Pharmacol 1986;31: 69-72.
Substantial rise in sparteine metabolic ratio during haloperidol treatment.
Several additional drugs have been identified for use in phenotyping studies, including sparteine and dextromethorphan, and more recently propafenone (Table 3) [16].
Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
